News
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.
Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...
Novo Nordisk A/S understated the impact of lookalike weight-loss injections on its market share before lowering its 2025 ...
3h
Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
When it was riding high, Novo Nordisk could have done M&A to reduce its dependence on obesity treatments. It didn’t.
Russia is currently experiencing a boom in the sales of Ozempic (semaglutide) and its analogues due to a high demand for such drugs among domestic customers, reports The Pharma Letter’s local ...
4dOpinion
Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.
Stocktwits on MSN1h
Novo Nordisk Downgraded By UBS Over Uncertain Outlook For Wegovy, But Retail Prefers To Look At The Sunny SideNYSE-listed shares of Danish drugmaker Novo Nordisk (NVO) fell about 3% on Tuesday morning after brokerage UBS downgraded the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback